US6047491013
US6047491013
Mirum Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 521.312.000 | 336.888.000 | 54.7% |
| Cost of Revenue | 100.240.000 | 81.643.000 | 22.8% |
| Gross Profit | 421.072.000 | 255.245.000 | 65.0% |
| 443.208.000 | 342.851.000 | 29.3% | |
| Operating Income | -22.136.000 | -87.606.000 | 74.7% |
| Pretax Income | -21.427.000 | -86.912.000 | 75.3% |
| Net Income Common Stockholders | -23.363.000 | -87.942.000 | 73.4% |
| -- | -- | -- | |
| -- | -- | -- |